XML 78 R67.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Share-Based Compensation Level 4 (Details)
6 Months Ended
Jun. 30, 2011
Stock Options [Member]
 
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]  
Dividend yield 2.40%
Expected volatility 38.40%
Risk-free interest rate 2.40%
Expected holding period 5.0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]  
Options outstanding at beggining of period 12,312,783
Options outstanding at beginning of period, weighted average exercise price 7.53
Granted 2,394,430
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9.09
Exercised 1,055,758
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6.73
Cancelled (94,857)
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 5.32
Options outstanding at end of period 13,556,598
Options outstanding at end of period, weighted average exercise price 7.88
Options exercisable at June 30, 2011 8,369,351
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price 8.15
Restricted Stock [Member]
 
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested [Roll Forward]  
Nonvested restricted shares at beginning of period 1,167,273
Nonvested restricted shares at beginning of period, weighted average exercise price 6.35
Granted 538,620
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value 9.13
Vested (540,723)
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value 6.58
Nonvested restricted shares at end of period 1,165,170
Nonvested restricted shares at end of period, weighted average exercise price 7.53